<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Maplight Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Maplight Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/maplight-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third</description>
</item>
<item>
<title>MapLight Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team</description>
</item>
<item>
<title>MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-updates-expected-timing-120000806</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-updates-expected-timing-120000806</guid>
<pubDate>Fri, 09 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company’s Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robustly, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomiz</description>
</item>
<item>
<title>MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-receives-fast-track-120000005</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-receives-fast-track-120000005</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (“MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapi</description>
</item>
<item>
<title>SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/sandboxaq-maplight-therapeutics-announce-strategic-120000566</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/sandboxaq-maplight-therapeutics-announce-strategic-120000566</guid>
<pubDate>Tue, 16 Dec 2025 12:00:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- SandboxAQ and MapLight Therapeutics, Inc. (Nasdaq: MPLT) announced today that the companies have entered into a strategic collaboration to discover and develop potential first-in-class therapies targeting a novel G protein-coupled receptor (GPCR) for the treatment of central nervous system (CNS) disorders. Under the terms of the agreement, SandboxAQ received an upfront payment and will be eligible to receive additional preclinical, deve</description>
</item>
<item>
<title>MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-reports-third-quarter-120000230</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-reports-third-quarter-120000230</guid>
<pubDate>Thu, 04 Dec 2025 12:00:00 GMT</pubDate>
<description>Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE</description>
</item>
<item>
<title>MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-announces-closing-initial-130600353</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-announces-closing-initial-130600353</guid>
<pubDate>Wed, 29 Oct 2025 13:06:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the closing of its initial public offering of 16,962,500 shares of common stock at an initial public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 2,212,500 sh</description>
</item>
<item>
<title>MapLight Therapeutics Announces Pricing of Initial Public Offering</title>
<link>https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-announces-pricing-initial-213000673</link>
<guid isPermaLink="true">https://6ix.com/company/maplight-therapeutics-inc-common-stock/news/maplight-therapeutics-announces-pricing-initial-213000673</guid>
<pubDate>Sun, 26 Oct 2025 21:30:00 GMT</pubDate>
<description>SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today announced the pricing of its initial public offering of 14,750,000 shares of common stock at an initial public offering price of $17.00 per share. In addition, MapLight has granted the underwriters a 30-day option to purchase up to an additional 2,212,500 s</description>
</item>
</channel>
</rss>